and sepsis in a tertiary care 30-bedded chemotherapy oncology unit is the first human outbreak to the best of our knowledge.
Background. Isavuconazole is a broad-spectrum antifungal available in both intravenous (IV) and oral capsule formulations for the treatment of invasive aspergillosis and mucormycosis. Oral administration can be challenging as FDA prescribing information states capsules should not be chewed, crushed, dissolved, or opened. We describe the first two cases, to our knowledge, of patients who received isavuconazonium capsules sprinkled via NGT with concomitant therapeutic drug monitoring (TDM).
Methods. All ISA serum and plasma assays resulted from January 1, 2016 to February 1, 2018 at a tertiary academic medical center were assessed. Isavuconazole assays were performed by Viracor Eurofins, Inc. using liquid chromatography-tandem mass spectrometry. Retrospective chart review was performed for all patients. Assay results from patients receiving whole capsules by mouth (PO) were compared with NGT.
Results. Nineteen unique patients had 33 ISA assays during the study period. Two patients received capsules via NGT. The first patient was a 59-year-old female treated empirically for fungal rhinosinusitis who received 5 days of IV therapy prior to switching to NGT. Trough ISA levels on days 11 and 23 were 1.9 and 1.5 μg/mL, respectively. The second patient was a 66-year-old male treated for presumed invasive pulmonary aspergillosis who received 7 days of NGT therapy; trough level on day 8 was 2.9 μg/mL. Both patients received continuous tube feedings and were liver transplant recipients. In comparison, trough concentrations in the PO group (N = 17) ranged from 1.1 to 8.0 μg/ mL (3.79 ± 1.68). All patients received FDA-approved loading and maintenance dosing.
Conclusion. Patients receiving isavuconazonium via NGT (opened sprinkled capsules) achieved clinically detectable serum ISA levels in a therapeutic range comparable to patients receiving PO. This study provides the first evidence that enteral routes other than PO may be effective for isavuconazonium administration. While the establishment of a trough concentration threshold predicting ISA therapeutic efficacy remains to be determined, TDM in patients receiving capsules by an enteral route other than PO may play an important role. Background. Candidemia is a major life-threatening fungal infection in hospitalized patients worldwide. In 2014, South Korea's national health insurance expanded its coverage for newer antifungal agents such as echinocandins. This study investigated the effects of change in insurance coverage on the prescription patterns of antifungals, medical costs, and treatment outcomes of candidemia.
Methods. A retrospective cohort study was conducted for all hospitalized patients with candidemia at three tertiary care hospitals in South Korea from January 2012 to December 2015. The utilization of antifungal agents, medical cost, and treatment outcomes before and after the healthcare benefit expansion were compared and the factors associated with 28-day mortality during the study period were analyzed.
Results. A total of 769 candidemia patients were identified during the study period: from 2012 to 2015, there were 196, 199, 201 , and 173 patients, respectively. The incidence of candidemia did not change during the study period (P = 0.253). The proportion of echinocandins as the initial antifungal agent and direct medical costs for candidemia significantly increased since the change in insurance coverage (P < 0.001). There was no significant difference in 28-day mortality of candidemia before and after the healthcare benefit expansion (P = 0.067). On multivariable analysis, independent factors associated with the 28-day mortality were Charlson comorbidity score (odds ratio Conclusion. Although the utilization of newer antifungal agents and medical cost for candidemia has significantly increased since the healthcare benefit expansion, to include newer antifungal agents, the policy change does not seem to change the mortality rate of candidemia in South Korea.
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